Avalo Therapeutics (AVTX) Cash from Financing Activities (2014 - 2026)

Avalo Therapeutics has reported Cash from Financing Activities for 13 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities changed N/A year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $16.0 million (down 76.22% YoY), and the FY2025 full-year result was $14.6 million, down 91.7% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $1.4 million, up from $687000.0 in the prior quarter.
• The five-year high for Cash from Financing Activities was $108.6 million in Q1 2024, with the low at -$14.8 million in Q2 2022.
• Historically, Cash from Financing Activities has averaged $15.6 million across 5 years, with a median of $687000.0 in 2025.
• The largest YoY upside for Cash from Financing Activities was 6770800.0% in 2024 against a maximum downside of 178.93% in 2024.
• Avalo Therapeutics' Cash from Financing Activities stood at $82000.0 in 2022, then sank by 98.78% to $1000.0 in 2023, then jumped by 6770800.0% to $67.7 million in 2024, then slumped by 98.99% to $687000.0 in 2025, then jumped by 103.64% to $1.4 million in 2026.
• The last three Cash from Financing Activities figures came in at $1.4 million (Q1 2026), $687000.0 (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.